جست‌وجوی استاد و پژوهشگر

Harris H. Wangمشاهده پروفایل

دانشیار

• Systems Biology
• Synthetic Biology
• Genome Engineering
• +۱۷ مورد دیگر

Harris H. Wang is an Associate Professor in the Department of Systems Biology and Department of Pathology and Cell Biology at Columbia University's Vagelos College of Physicians and Surgeons, where he also serves as Interim Chair of Systems Biology. He is affiliated with the Center for Computational Biology and Bioinformatics (C2B2) and the Integrated Program in Cellular, Molecular and Biomedical Studies (CMBS). B.S., Physics and Mathematics, MIT Ph.D., Biophysics, Harvard University Dr. Wang's research lies at the intersection of systems and synthetic biology, focusing on developing foundational technologies for genome engineering, microbiome manipulation, and synthetic genomics. His lab pioneers methods such as MAGE, MAGIC, CAST, and CAMII to enable high-throughput genetic manipulation, in situ microbiome engineering, and AI-driven microbial culturomics. Key research themes include understanding microbial community dynamics, engineering cellular memory systems, designing biocontained genetic circuits, and applying synthetic biology to human health challenges in personalized medicine and infectious disease. His recent publications reveal a strong trend in spatial and functional metagenomics, CRISPR-based microbiome editing, and synthetic biology tools for data storage and genetic stability. The articles span high-impact journals like Nature , Science , and Nature Biotechnology , reflecting his leadership in developing scalable, programmable biological systems. Scientific Awards: NIH Director’s Early Independence Award Forbes 30 Under 30 in Science Sloan Research Fellowship NSF CAREER Award ONR Young Investigator Award Burroughs Wellcome Fund PATH Award Schaefer Scholar Blavatnik National Award Vilcek Prize PECASE Dr. Wang has advised numerous PhD and postdoctoral researchers, many of whom have gone on to independent scientific careers. His lab is supported by major grants from NIH, NSF, DARPA, DOE, and foundations including the Bill & Melinda Gates Foundation and CZ Biohub NY. He is actively involved in educational initiatives, including organizing Columbia’s iGEM team and the Cold Spring Harbor Laboratory Synthetic Biology course. The Wang Lab is based at the Columbia University Irving Medical Center and is part of national consortia such as the Engineering Biology Research Consortium (EBRC) and the Genome Project-Write (GP-Write) initiative. The lab develops and applies cutting-edge technologies in automation, machine learning, and synthetic biology to engineer microbiomes for applications in medicine, global health, and climate change.

• Immunology
• Translational Immunology
• Computational Immunology
• +۴ مورد دیگر

Professor Mark Coles serves as Professor of Immunology and Lead for Industrial Strategy and Entrepreneurship at the Kennedy Institute of Rheumatology, University of Oxford, holding concurrent roles as Kennedy Trust Senior Research Fellow, Official Fellow at Reuben College, and Affiliate Faculty at the Wolfson Centre of Mathematical Biology. His interdisciplinary work bridges immunology, computational modeling, and translational research to accelerate therapies for immune-mediated inflammatory diseases. His academic journey began with a BSc in Microbiology from Cornell University (1992), followed by a PhD in Molecular and Cell Biology at UC Berkeley under David Raulet, and postdoctoral training with Dimitris Kioussis at the National Institute of Medical Research. At the University of York (2006-2017), he pioneered stromal immunology research and co-founded the York Computational Immunology Laboratory. Coles' research centers on stromal and systems immunology, with core expertise in stromal cell biology, inflammatory disease mechanisms, and mathematical modeling of immune responses. He champions 3Rs-based approaches (Replacement, Reduction, Refinement) to reduce animal testing through in silico models, integrating spatial single-cell biology with multi-scale computational frameworks to dissect immune function in human tissues. His 2025 publications reveal a cohesive research trajectory applying interdisciplinary methods across diverse disease contexts—from cardiac fibrosis and vaccine responses to arthritis pathogenesis and CAR-T cell therapy—unified by focus on stromal-immune crosstalk and quantitative modeling to identify therapeutic targets. Key honors include: Fellow of the Royal Society of Biology Kennedy Trust Senior Research Fellow As former Director of Graduate Studies (2017-2024) at the Kennedy Institute, Coles mentored numerous graduate students while co-leading major initiatives including the Arthritis Therapy Acceleration Program and Human Cell Atlas medicalization. His entrepreneurial impact spans three co-founded ventures: Simomics Ltd (in silico disease modeling), Lightox Ltd (phototherapy for oral cancer), and Mestag Therapeutics (fibroblast-targeted therapies for cancer/inflammation). He directs the Laboratory of Stromal and Systems Immunology and Oxford Mathematical Immunology Group, fostering collaborations with Christopher Buckley, Calliope Dendrou, and Eamonn Gaffney to develop Quantitative Systems Pharmacology models that translate mechanistic insights into patient therapies.

• Immunology
• Genomics
• Multiomics Analysis
• +۳ مورد دیگر

Calliope Dendrou is an Associate Professor in Clinical Pathology and Inflammation at the Kennedy Institute of Rheumatology (KIR), University of Oxford, leading the Immune Disease Multiomics Laboratory. She previously held a Wellcome & Royal Society Sir Henry Dale Fellowship at the University of Oxford’s Centre for Human Genetics before joining KIR in 2023. Her research focuses on immune disease mechanisms using multiomics approaches, including genomic profiling to identify therapeutic targets across tissues and immune-mediated diseases. She co-leads large-scale projects like the Oxford-J&J Cartography Consortium and the Chan Zuckerberg Initiative’s LEGACY Network, and teaches on the MSc in Genomic Medicine program. Educational Background: BSc (Biology, Imperial College London, 2005; Forbes Memorial Medal Winner); PhD in Infection & Immunity (University of Cambridge, 2010). Postdoctoral training at the Weatherall Institute of Molecular Medicine under Prof. Lars Fugger. Research interests include immunogenetics, cytokine signaling pathways, drug repositioning, and cross-disease pathophysiology. Her work integrates single-cell and spatial transcriptomics to dissect immune-cell interactions in diseases like rheumatoid arthritis, inflammatory bowel disease, and celiac disease. Recent articles highlight her contributions to understanding vaccine adjuvant responses, Th17 cell roles in spondyloarthritis, and immune-epithelial networks in celiac disease. Collaborations emphasize multi-omic data analysis (e.g., Panpipes pipeline) and translational studies toward precision medicine. Awards: Forbes Memorial Medal (BSc), Wellcome & Royal Society Sir Henry Dale Fellowship. Leadership roles include Equality, Diversity, and Inclusion Champion and 'Single-Cell & Spatial Omics for Precision Medicine' Module Lead. Lab & Teams: Immune Disease Multiomics Lab at KIR. Active in collaborative initiatives such as the LEGACY Network, focusing on large-scale immune profiling in ancestrally diverse populations.

Naresh R. Shanbhagمشاهده پروفایل

استاد

• Energy-efficient computing
• Machine learning hardware
• In-memory computing
• +۷ مورد دیگر

Naresh R. Shanbhag is the Jack Kilby Professor in the Department of Electrical and Computer Engineering and the Coordinated Science Laboratory at the University of Illinois at Urbana-Champaign. He serves as Director of the Systems on Nanoscale Information fabriCs (SONIC) Center and held the D.J. Gandhi Distinguished Visiting Professorship at IIT Mumbai from 2015-2020. Previously, he was a visiting faculty member at National Taiwan University (2007) and Stanford University (2014). Dr. Shanbhag received his doctorate from the University of Minnesota (1993) in Electrical Engineering. From 1993 to 1995, he worked at AT&T Bell Laboratories as the lead chip architect for AT&T's 51.84 Mb/s transceiver chips over twisted-pair wiring for Asynchronous Transfer Mode (ATM)-LAN and very high-speed digital subscriber line (VDSL) chip-sets. His research focuses on the design of energy-efficient machine learning, communications, and signal processing systems on resource-constrained embedded platforms. He explores fundamental trade-offs between energy efficiency, latency and accuracy of decision-making systems implemented in nanoscale technologies, with applications to computer vision, biomedicine, automatic target recognition, and imaging. His work spans four primary focus areas: Resource-efficient Machine Learning for the Edge, In-memory Computing (IMC), Energy-efficient High Data Rate Communications, and Shannon-inspired Statistical Error Compensation (SEC). Analysis of his recent publications reveals a strong emphasis on in-memory computing architectures (SRAM, MRAM, RRAM) for machine learning acceleration. His work consistently addresses energy-accuracy trade-offs, with increasing attention to security aspects of hardware implementations and applications to MIMO signal processing and edge AI systems. His research demonstrates a progression from theoretical foundations to practical silicon implementations. 2024 Semiconductor Research Corporation Innovation Award 2018 Semiconductor Industry Association/Semiconductor Research Corporation University Researcher Award 2018 IEEE International Symposium on Circuits and Systems Best Paper Award 2006 IEEE Fellow 1996 National Science Foundation CAREER Award Professor Shanbhag has mentored over 50 graduate students who now work at leading technology companies including Qualcomm, Amazon, Nvidia, Intel, and Apple. His research has been generously supported by the National Science Foundation, DARPA, AFRL, Semiconductor Research Corporation, Texas Instruments, Sandia National Laboratories, and industry partners including IBM, GlobalFoundries, and Intel Corporation. He led the Alternative Computational Models research theme (2006-2012) and was the founding Director of the SONIC Center (2013-2017), a 5-year multi-university center funded by DARPA and SRC. Currently, he leads research themes in the SRC and DARPA funded JUMP 2.0 Program's Center for Co-Design of Cognitive Systems and the Center for Ubiquitous Connectivity, and in the NSF IUCRC Center for Advanced Semiconductor Chips with Accelerated Performance (ASAP). As Director of the Systems on Nanoscale Information fabriCs (SONIC) Center, Professor Shanbhag leads a multidisciplinary team exploring novel computing paradigms for the nanoscale era. His group has benchmarked an extensive collection of in-memory computing and digital accelerator IC designs, maintaining a publicly available IMC benchmarking repository of metrics extracted from published IC prototypes. His research philosophy integrates concepts from information theory, statistical signal processing, detection and estimation, VLSI architectures, and digital and analog integrated circuits to develop energy-efficient systems from algorithms to silicon implementations.

Waldemar Kolanusمشاهده پروفایل

استاد

• Molecular Immunology
• Cell Signaling
• Signal Transduction Pathways
• +۴ مورد دیگر

Prof. Waldemar Kolanus leads the Molecular Immunology and Cell Biology department at the University of Bonn's Life & Medical Sciences Institute (LIMES) . His research bridges immunoregulation , stem cell dynamics , and metabolic stress responses in immune cells. Unit 2 member at LIMES Principal investigator in SFB 704 and ImmunoSensation Cluster Leads a multidisciplinary lab with postdocs, PhD students, and technical staff His work focuses on intracellular signaling pathways connecting immune activation to tissue homeostasis, particularly through: Cytohesin proteins in integrin-mediated adhesion and migration TRIM71 in stem cell regulation and congenital hydrocephalus High-salt environments affecting macrophage function Publication trends show expertise in immune cell migration , genetic models , and chemical inhibition , with frequent use of mice and zebrafish for in vivo studies. Key articles explore: TRIM71's dual role in auditory development and germ cell maintenance Cytohesin family's Golgi regulation and insulin signaling Ruxolitinib's off-target migration inhibition of dendritic cells Contact details: Address: LIMES Institute, Carl-Troll-Straße 31, Bonn Email: kolanus.sekretariat@uni-bonn.de Phone: +49 228 73-62788

• Neurovascular Surgery
• Cerebrovascular Disorders
• Stroke Intervention
• +۳ مورد دیگر

Ryan M Hebert, MD, is an Assistant Professor of Neurosurgery at the Yale School of Medicine, affiliated with the Neurosurgery department. He specializes in neurovascular disorders, including open and endovascular treatments for intracranial aneurysms, arteriovenous malformations, carotid disease, and dural arteriovenous fistulas. He also focuses on interventions for ischemic and hemorrhagic strokes. His practice locations include Yale New Haven Hospital and Lawrence and Memorial Hospitals in Connecticut. Education & Training: Bachelor’s in Molecular, Cellular, and Developmental Biology from the University of Colorado – Boulder (Howard Hughes Undergraduate Research Grant recipient) MD from Yale School of Medicine (NIH-funded thesis on CCM3 in cerebral cavernous malformations) 7-year Neurosurgery Residency at Yale New Haven Hospital, including enfolded neuro-interventional training CAST-accredited fellowship in Endovascular Neurosurgery and Neurovascular Critical Care at Thomas Jefferson University Hospital (2016) Research Interests: Dr. Hebert’s work centers on emerging surgical and endovascular techniques for neurovascular disorders, risk stratification in carotid disease, vasospasm prediction/post-subarachnoid hemorrhage treatment, and outcomes of minimally invasive spine surgery. His studies often integrate clinical practice with translational research, emphasizing patient outcomes and procedural optimization. Key topics include flow diverters, cranial nerve palsies, hospital frailty risk scores, and immune mechanisms driving aneurysm rupture. Publications Trends: His recent articles emphasize clinical outcomes of endovascular procedures, stroke interventions, and immune mechanisms in aneurysm rupture. He frequently collaborates on meta-analyses and systematic reviews to evaluate treatment efficacy and complication rates, particularly involving cranial nerve recovery and thrombectomy volumes. Awards & Grants: He secured an NIH-funded thesis and a Howard Hughes Undergraduate research grant. No explicit scientific awards are listed, but his work has been recognized via peer-reviewed publications and contributions to clinical guidelines. Advising & Grants: While no students are listed, he collaborates with prominent researchers like Charles Matouk, Kevin Sheth, and Joseph Antonios on NIH-funded projects. His research addresses healthcare resource utilization and procedural volume impacts on mortality, indicating a focus on translational and clinical studies. Labs & Teams: Active in interdisciplinary teams at Yale School of Medicine, particularly in neurovascular critical care and endovascular surgery. Collaborates with the Stroke Center and Janeway Society for physician-scientist development.

Kenneth Hoehnمشاهده پروفایل

استادیار

• Computational Immunology
• Evolutionary Biology
• B Cell Biology
• +۵ مورد دیگر

Kenneth Hoehn is an Assistant Professor in the Department of Biomedical Data Science at the Geisel School of Medicine, Dartmouth College. As a computational immunologist with expertise in evolutionary biology, he develops computational evolutionary approaches to trace cellular lineages, particularly B cells, in contexts such as infection, vaccination, cancer, and autoimmune diseases. His research focuses on understanding adaptive immunity in conditions like COVID-19 Food allergies Myasthenia gravis through collaborations with experimental teams. Key projects include: Phylogenetic modeling of B cell responses Evolutionary signatures in immune repertoires Tracking B cell dissemination in autoimmune diseases Epigenetic regulation of memory B cells Recent publications highlight trends in single-cell immunology , phylogenetic inference , and computational tools for analyzing B cell dynamics. His lab at Dartmouth integrates evolutionary genetics with high-resolution immune profiling.

• Cancer Biology
• Mathematical and Computational Modeling
• Bioinformatics
• +۷ مورد دیگر

Dana Pe'er is a Professor and Chair of the Computational and Systems Biology Program at the Sloan Kettering Institute (SKI) of Memorial Sloan Kettering Cancer Center. She is also an Investigator of the Howard Hughes Medical Institute and holds the Alan and Sandra Gerry Endowed Chair. Dr. Pe'er leads an interdisciplinary research group that combines advanced genomics approaches with machine learning to address fundamental questions in biomedical science, with particular focus on cancer biology, developmental biology, and immunology. Dr. Pe'er earned her PhD from Hebrew University in Jerusalem, Israel. Her academic journey includes a postdoctoral fellowship with George Church at Harvard Medical School. Before joining Memorial Sloan Kettering Cancer Center in 2016, she held faculty positions at Columbia University. Dr. Pe'er's research focuses on understanding cellular plasticity, the consequences of intra-tumor heterogeneity, cancer evolution and metastasis, and the mechanisms by which regulatory circuits go awry in disease. Her lab combines single-cell and spatial profiling technologies with machine learning approaches to investigate gene regulation, cellular plasticity, and cell-cell communication in the contexts of cancer, immunity, and development. They are particularly interested in how organisms develop from a single cell to generate diverse cell types, how epigenetic control rewires during development, and how cells communicate to execute multicellular responses. Analysis of Dr. Pe'er's recent publications reveals a strong focus on developing computational methods for single-cell and spatial genomics data analysis. Her work spans cancer types including pancreatic, prostate, colorectal, and breast cancer, with emphasis on tumor heterogeneity, metastasis mechanisms, and cellular plasticity. A significant portion of her research involves creating novel algorithms and tools like CellRank, REUNION, and SEACells that enable researchers to extract meaningful biological insights from complex genomic datasets. 2023 Class of 2023 Inductee - American Academy of Cancer Research (AACR) Academy 2023 Innovator Award - International Society for Computational Biology (ISCB) 2021 Fellow - International Society for Computational Biology (ISCB) Howard Hughes Medical Institute Investigator (2021) 2019 Ernst W. Bertner Memorial Award - University of Texas MD Anderson Cancer Center 2016 Lenfest Distinguished Faculty Award - Columbia University 2014 Director's Pioneer Award - National Institutes of Health 2014 Overton Prize - International Society for Computational Biology (ISCB) Dr. Pe'er is known for her dedicated mentorship approach, describing herself as "a mama bear" who cares deeply about her trainees while expecting independence, innovation, and hard work. She mentors numerous PhD students and postdocs in her lab. Her HHMI Investigator award provides approximately $9 million over seven years, enabling ambitious research directions. She also collaborates extensively with the Single-cell Analytics and Innovation Lab (SAIL) at MSK to generate new data from emerging technologies, working closely with wet-lab collaborators at MSK and beyond to apply computational methods to cutting-edge datasets across multiple disease areas. The Pe'er Lab is an interdisciplinary group of computational biologists with diverse backgrounds ranging from pure mathematics to clinical medicine. They work closely with wet-lab collaborators to apply their computational methods to cutting-edge datasets across cancer, immunology, and developmental biology. The lab is described as open, supportive, collaborative, and fun, with access to world-class facilities at the Sloan Kettering Institute. Dr. Pe'er's work continues to push the boundaries of computational biology and cancer research, with the ultimate goal of developing more effective, personalized therapies for cancer patients.

• Immunodeficiency Diseases
• Actin Regulators in Immune Cells
• Autoimmunity
• +۳ مورد دیگر

Lisa Westerberg is a Professor of Experimental Immunology at the Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet. Her research focuses on understanding how compromised immune systems lead to immunodeficiency, autoimmunity, and hematological cancers, particularly studying the role of actin regulators in immune cell function. She leads the 'Immunodeficiency Diseases – Lisa Westerberg Group' and collaborates internationally with institutions like Harvard Medical School and the University College London. Education: PhD in Cell and Molecular Biology from Karolinska Institutet (2003), postdoc at Harvard Medical School (2009). Affiliations: Department of Microbiology, Tumor and Cell Biology; WASPSTINGS network (STINT-funded); Swedish Society for Immunology (Treasurer). Research Interests: Immunodeficiency diseases, actin cytoskeleton dynamics in immune cells, cancer immunology, and space immunology. Her lab investigates how genetic mutations in actin regulators affect immune cell communication, migration, and genomic stability. Recent projects include studying immune system adaptation in microgravity and developing therapies targeting actin regulators in cancer. Articles Trends: Recent work highlights immune cell adaptations in space environments, therapeutic modulation of actin pathways, and clonal evolution in lymphomas. Over 15 articles since 2020 explore mechanisms linking immune dysfunction to cancer and immunodeficiency. Awards: Ragnar Söderberg Fellowship, ERC Starting Grant (2019), Wallenberg Academy Fellow. Funding: Swedish Research Council, Knut och Alice Wallenberg Foundation, EU grants. Advising & Grants: Supervised over 40 students (PhD, Master’s, undergrad) since 2010. Active in training programs like the Amgen Scholars initiative. Collaborates with global teams on projects funded by VR, NIH, and international partnerships. Labs/Teams: Leads the core Immunodeficiency Diseases Group and collaborates with the Dosenovic Lab (focusing on B cell vaccine development). The group uses CRISPR, high-resolution microscopy, and single-cell sequencing to study immune mechanisms.

Li Tangمشاهده پروفایل

دانشیار

• Immunoengineering
• Cancer Immunotherapy
• Immune Metabolism
• +۷ مورد دیگر

Li Tang is an Associate Professor with tenure at École polytechnique fédérale de Lausanne (EPFL), affiliated with the Institute of Bioengineering (IBI) and the Institute of Materials Science and Engineering (IMX) within the School of Engineering (STI). She leads the Laboratory of Biomaterials for Immunoengineering, focusing on developing innovative strategies at the intersection of immunology, materials science, and cancer therapy. Her work bridges fundamental research and clinical translation, with multiple ongoing clinical trials based on CAR-T cell therapies developed in her lab. B.S. in Chemistry, Peking University (2003–2007) Ph.D. in Materials Science and Engineering, University of Illinois at Urbana-Champaign (2007–2012) Postdoctoral Fellow, MIT (2013–2016) Her research lies at the forefront of immunoengineering, integrating chemical, metabolic, and mechanical approaches to modulate immune responses. Key areas include cancer immunotherapy, immune metabolism, mechano-immunology, and biomaterials. She investigates how physical and biochemical cues can reprogram T cells, overcome exhaustion, and enhance tumor targeting. Her work emphasizes multidimensional immunity-disease interactions, aiming to develop safer and more effective therapies for cancer and autoimmune diseases. The recent publications highlight a strong trend in engineering immune cells (especially CAR-T) for enhanced durability and function, using advanced biomaterials and metabolic reprogramming. There is a clear focus on overcoming challenges in solid tumors, modulating the tumor microenvironment, and translating findings into clinical applications. The use of nanoparticle delivery, single-cell analysis, and biomechanical cues are recurring themes across her work. Notable scientific awards include: Friedrich Miescher Award (2025) ERC Starting Grant (2018) MIT TR35 Innovators Under 35 (China Region, 2020) Nano Research Young Innovator Award (2018) Biomaterials Science Emerging Investigator (2019) Materials Horizons Emerging Investigator (2020) Li Tang actively mentors PhD students across multiple doctoral programs (EDBB, EDMS, EDMX) and has advised numerous graduates who have gone on to prestigious postdoctoral and faculty positions. She is involved in significant research grants, including an Innosuisse project with Novochizol SA, and her lab is supported by competitive funding. She teaches core courses such as Immunoengineering and Next-Generation Biomaterials, shaping the next generation of scientists. Her lab fosters interdisciplinary collaboration and innovation, with active projects in chemical, metabolic, and mechanical immunoengineering, as well as CAR-T cell development. She is the Principal Investigator of the Tang Lab, which includes postdoctoral fellows, PhD students, and technical staff. The lab is actively recruiting and has a strong publication and clinical translation record. Tang Lab is also involved in multiple MA/BA training projects and promotes student engagement in cutting-edge research. The lab’s discoveries are being translated into clinical trials, reflecting a strong commitment to translational science.

Peter A. Jonesمشاهده پروفایل

استاد

• Epigenetics
• DNA methylation
• Cancer epigenetics
• +۷ مورد دیگر

Peter A. Jones is President and Chief Scientific Officer at the Van Andel Institute (VAI) in Grand Rapids, Michigan, where he leads the Department of Epigenetics. He previously served as Director of the USC Norris Comprehensive Cancer Center from 1993 to 2011 and has been a central figure in advancing epigenetics research, particularly in cancer. His laboratory investigates DNA methylation, chromatin dynamics, and epigenetic therapies. Research Interests: Dr. Jones's work centers on epigenetic mechanisms in cancer, including DNA methylation, histone modifications, nucleosome positioning, and the therapeutic potential of epigenetic drugs. His research has pioneered the use of DNA methylation inhibitors like 5-azacytidine and explored viral mimicry as a mechanism for immune activation in cancer. He also studies transposable elements and their role in gene regulation and immune response. Publication Trends: His recent publications (2021–2024) reveal a strong focus on the interplay between epigenetics and immunotherapy, particularly how DNA methyltransferase inhibitors (DNMTi) induce viral mimicry, enhance immune recognition, and improve responses to checkpoint blockade. Studies span hematological malignancies, solid tumors, and T cell biology, with frequent collaboration with Stephen Baylin and others. Scientific Awards: Member, National Academy of Sciences Member, National Academy of Medicine Fellow, AACR Academy Fellow, AAAS Fellow, American Academy of Arts and Sciences Kirk A. Landon Award for Basic Cancer Research (2009) Medal of Honor, American Cancer Society (2011) Outstanding Investigator Grant, NCI Harvey Prize (2024) Advising and Grants: Dr. Jones mentors multiple postdoctoral fellows, graduate students, and research scientists. His lab is supported by major grants, including the VAI-SU2C Epigenetics Dream Team, which has launched 15 clinical trials. He has received sustained funding from the National Cancer Institute and collaborates with institutions worldwide to advance epigenetic therapies. Labs and Teams: He leads the Peter Jones Laboratory at VAI, a multidisciplinary team investigating epigenetic regulation in cancer. The lab includes computational biologists, clinical researchers, and molecular biologists, working on both basic mechanisms and translational applications. The team is part of larger collaborative initiatives such as the VAI-SU2C Epigenetics Dream Team and the International Linked Clinical Trials Program.

Caetano Reis e Sousaمشاهده پروفایل

استاد

• Immunology
• Infectious Disease
• Cancer Immunotherapy
• +۳ مورد دیگر

Caetano Reis e Sousa is a Professor of Immunology at Imperial College London and Senior Group Leader/Assistant Research Director at the Francis Crick Institute. He leads the Immunobiology Laboratory, focusing on dendritic cell biology, immune responses to pathogens, and cancer immunotherapy. His research explores how dendritic cells detect pathogens and dying cells, triggering adaptive immunity. Key roles include investigating cross-presentation mechanisms, C-type lectin receptors (e.g., DNGR-1), and vaccine development strategies. Education: BSc (Hons) Biology from Imperial College London (1989), DPhil in Immunology from University of Oxford (1992). Postdoctoral training at NIH under Ron Germain. Career milestones include founding the Immunobiology Lab at CRUK London Research Institute (1998–2015) before joining the Crick. Awards & Recognition: Highly Cited Researcher (Thomson Reuters), BD Biosciences Prize (2002), Liliane Bettencourt Award (2008), Louis-Jeantet Prize (2017), Fellowships at Royal Society (2019), Academy of Medical Sciences (2006), and EMBO (2006). Named Officer of the Order of Sant'Iago da Espada (Portugal, 2009). Research Themes: Dendritic cell activation pathways, cross-presentation of tumor antigens, microbiome-cancer immunity links, and immune evasion mechanisms. Collaborations involve institutions like UCL, King's College London, and global health networks. Labs/Teams: Head of Immunobiology Lab at Crick, with expertise in immunology, cell biology, and virology. Facilities include Flow Cytometry, Genomics, and Light Microscopy cores. Active in pandemic response (e.g., SARS-CoV-2 testing initiatives).

• Rheumatology
• Inflammatory Diseases
• Fibroblast Biology
• +۳ مورد دیگر

Christopher Buckley is the Kennedy Professor of Translational Rheumatology and Director of Clinical Research at the Kennedy Institute of Rheumatology, University of Oxford. He holds concurrent roles as Director of NIHR Infrastructure for Birmingham Health Partners. His research focuses on fibroblast biology in rheumatoid arthritis (RA), stromal cell interactions, and translational medicine approaches to stratified therapy. He leads the Arthritis Therapy Acceleration Programme (A-TAP), advancing precision medicine strategies for immune-mediated inflammatory diseases. Educations: BSc Biochemistry, University of Oxford (1985) MBBS Medicine, Royal Free Hospital, London (1990) DPhil in Molecular Medicine (Wellcome Trust Fellowship) under Prof. John Bell (Oxford) Research Interests: Pathogenic fibroblast subpopulations in RA and systemic sclerosis Tissue-resident memory T cells in chronic inflammation Spatial transcriptomics of synovial and tendon tissues Pro-resolving fibroblast networks during inflammation resolution Development of biomarkers for disease flare/remission Awards & Leadership: MRC Senior Clinical Fellowship (2001) Arthritis Research UK Professorship (2002) Director, Birmingham NIHR Clinical Research Facility (2012-2017) Key Projects: Leading A-TAP's stratified pathology approach for drug development Investigating Wnt signaling in stromal inflammation Developing cellular atlases of joints using spatial transcriptomics

Christina Leslieمشاهده پروفایل

استاد پژوهشی

• Computational Biology
• Systems Biology
• Machine Learning
• +۷ مورد دیگر

Dr. Christina Leslie is a Research Professor and Member of the Computational & Systems Biology Program at Memorial Sloan Kettering Cancer Center (MSK). She leads an active research laboratory focused on developing computational approaches to understand complex biological systems. Dr. Leslie earned her PhD from the University of California, Berkeley and has established herself as a leading computational biologist in cancer research and immunology. Computational & Systems Biology Program, Memorial Sloan Kettering Cancer Center Gerstner Sloan Kettering Graduate School of Biomedical Sciences Dr. Leslie's research focuses on developing novel computational methods to study cellular biological systems from a global and data-driven perspective. Her lab exploits diverse high-throughput functional and genomic data to understand molecular networks underlying fundamental cellular processes, including transcription regulation, pre-mRNA processing, signaling, and post-transcriptional gene silencing. Her algorithmic methods draw heavily on machine learning to build accurate predictive models from noisy and high-dimensional biological data. Key areas of interest include modeling cell-type specific transcriptional programs and dissecting co- and post-transcriptional regulation, particularly microRNA-mediated gene regulation. Analysis of Dr. Leslie's publication record over the last five years reveals a strong focus on computational approaches to cancer genomics, immunology, and epigenetics. Her work bridges multiple disciplines, with a particular emphasis on developing machine learning methods to interpret complex biological data. The publications demonstrate increasing sophistication in integrating multiple data types (genomic, transcriptomic, epigenomic) to understand cancer biology and immune responses. Recent work shows a growing emphasis on single-cell technologies and spatial analysis of tumor microenvironments. Introduction of string kernel methodology for SVM classification of biological sequences Development of algorithms for predictive modeling of gene regulation First systems-level analyses of competition between microRNAs and between target transcripts Dr. Leslie actively mentors numerous graduate students and research associates, with current lab members including Vianne Gao, Alireza Karbalaghareh, Erik Ladewig, and several others. Her lab has received significant research funding to support their work on computational approaches to cancer biology and immunology. The Leslie Lab maintains close collaborations with multiple experimental groups at MSK, facilitating the translation of computational insights into biological understanding. The Leslie Lab operates within the Computational & Systems Biology Program at MSK, with strong ties to both the research and clinical missions of the institution. The lab maintains state-of-the-art computational infrastructure for analyzing large-scale genomic and proteomic datasets and collaborates extensively with wet-lab researchers to validate computational predictions experimentally.

Monica N. Fornierمشاهده پروفایل

پزشک-پژوهشگر

• Breast Cancer
• Medical Oncology
• Bone Health
• +۱ مورد دیگر

Monica N. Fornier is a physician scientist at Memorial Sloan Kettering Cancer Center (MSK) specializing in breast medical oncology . With a clinical focus on improving outcomes for breast cancer patients, she has particular expertise in bone health related to cancer therapies. Fluent in English, Italian, and French, Dr. Fornier treats international patients and contributes to multidisciplinary care teams. Education: MD from University of Milan (Italy), residency and fellowship at University Hospital of Milan and MSK Certifications: Board-certified in Internal Medicine and Medical Oncology (Europe) Her research spans neoadjuvant endocrine therapy , bone loss prevention in cancer patients, and HER2-positive breast cancer treatment beyond trastuzumab. Recent publications address ER+/HER2- breast cancer immune responses, alopecia management in survivors, and regulatory T cell mechanisms . Dr. Fornier has received multiple Castle Connolly Top Doctor awards (2023-2025) and participates in MSK clinical trials for novel cancer treatments.